All lobbying filings

AVENUE SOLUTIONS

Lobbying for VERTEX PHARMACEUTICALS INCORPORATED · Biopharmaceutical company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · Massachusetts · House · Senate · $60,000.00 income · posted Apr 21, 2025

Official filing document

Bills named in this filing 7

HR 1227
Alternatives to PAIN Act
S 475
Alternatives to PAIN Act
HR 1672
Maintaining Investments in New Innovation Act
HR 2484
Seniors’ Access to Critical Medications Act of 2025
HR 946
ORPHAN Cures Act
S 891
Bipartisan Health Care Act
HR 1968
Full-Year Continuing Appropriations and Extensions Act, 2025

Lobbying activity 2

Medicare/Medicaid

H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; H.R. 1672, Maintaining Investments in New Innovation Act; Biosimilars Access and Affordability Act; H.R. 2484, Seniors Access to Critical Medications Act; H.R. 946, ORPHAN Cures Act; Issues related to PBM reform

Health Issues

Monitor issues related to 340b; S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.